ORIC Pharmaceuticals Reports Q3 2025 Financial Results with $32.6 Million Net Loss

ORIC Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $32.6 million, a decrease from the $34.6 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company’s net loss totaled $99.0 million, compared to $91.5 million for the same period in the previous year. The company’s total operating expenses for the third quarter were $36.7 million, down from $38.3 million year-over-year, primarily due to reduced research and development costs associated with its lead product candidates, ORIC-944 and enozertinib.

In terms of financial position, ORIC Pharmaceuticals reported total assets of $431.2 million as of September 30, 2025, a significant increase from $274.1 million at the end of 2024. This growth was driven by an increase in cash and cash equivalents, which decreased to $49.7 million from $59.4 million, while short-term investments rose to $237.5 million from $196.6 million. The company’s accumulated deficit also increased to $661.7 million, reflecting ongoing investments in research and development.

Strategically, ORIC Pharmaceuticals has focused its resources on advancing its two lead clinical programs, ORIC-944 and enozertinib, following a strategic pipeline prioritization announced in August 2025. This decision led to a workforce reduction of approximately 20%, resulting in a one-time cost of about $1.9 million. The company has also engaged in several collaborations, including agreements with Johnson & Johnson and Bayer to evaluate its product candidates in combination with their therapies.

Operationally, ORIC Pharmaceuticals has made significant strides in its clinical trials. The company is currently conducting a Phase 1b trial for ORIC-944 in combination with apalutamide and darolutamide, with promising initial data reported. For enozertinib, the company is enrolling patients in a Phase 1b trial targeting advanced solid tumors with specific mutations. The company anticipates reporting further data and initiating a global Phase 3 trial for ORIC-944 in the first half of 2026.

Looking ahead, ORIC Pharmaceuticals expects to continue incurring significant losses as it advances its clinical programs. The company projects that its existing cash and investments will be sufficient to fund operations into the second half of 2028. However, it acknowledges the need for additional capital to support ongoing development and commercialization efforts, which may involve raising funds through equity or debt financing. The company remains focused on achieving regulatory approvals for its product candidates while navigating the uncertainties inherent in drug development.